Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Commentary|Articles|August 5, 2026
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
Author(s)Caroline Seymour
Fact checked by: Kyle Doherty
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Advertisement
Advertisement
OncLive® connected with gynecologic oncology experts at the
Related to this article
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
Selinexor maintenance failed to significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in the phase 3 XPORT-EC-042 trial.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.
New insights on early detection, cancer biology and surgical innovation in head and neck cancer highlighted at international research meeting.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Advertisement
Advertisement